The Academy of Managed Care Pharmacy (AMCP) thanks the Centers for Medicare and Medicaid Services (CMS) for the opportunity to provide comments in support of the notice titled “Medicare Part D Reporting Requirements and Supporting Regulations (CMS-10185)” published in the Federal Register on May 6, 2016. Under the notice, Part D sponsors would be responsible for submitting Medication Therapy Management (MTM) program reports as described in Title I, Part 423, Subpart D, § 423.153 for CY2017 by the last Monday of February in 2018.
The Academy of Managed Care Pharmacy (AMCP) supports Senate Bill 2313 –establishing a task force to study and analyze health insurance payer practices regarding the dispensing of specialty drugs directly to a patient or provider. AMCP recommends that the Committee add language including a managed care pharmacist as a member on the task force.
The Academy of Managed Care Pharmacy (AMCP) supports the passage of Senate Bill 1024. This bill would remove the December 31, 2016 sunset date currently in force which allows health care payment or benefit provider’s access to the state electronic system for monitoring schedules 2-5 controlled substances.
The undersigned pharmacy organizations would like to thank the Centers for Medicare and Medicaid Services (“CMS”) for the opportunity to comment on the Proposed Rule for the Medicare Program; Merit-Based Incentive Payment System and Alternative Payment Model Incentive under the Physician Fee Schedule (“PFS”), and Criteria for Physician-Focused Payment Models (the “Proposed Rule”).
On June 15, 2016, the Medicare Payment Advisory Commission (MedPAC)1 released its June 2016 Report to the Congress: Medicare and the Health Care Delivery System2. Of the 347-page report, three chapters focus on examining policy issues related to prescription drugs, with a particular focus around “rapid growth in drug prices, which can affect beneficiary access to needed medications, as well as the financial sustainability of the Medicare program.”
The Academy of Managed Care Pharmacy (AMCP) is writing to express our opposition to certain mandated provisions in S. 3419 – C, an act establishing and mandating requirements for step therapy programs used by insurers, et al. This legislation as proposed would impose unnecessary additional requirements for an insurer’s step therapy program.
The Academy of Managed Care Pharmacy (AMCP) acknowledges that abuse deterrent opioid analgesic drug products are appropriately prescribed for certain patients, but should not be required by state mandates. For this reason, AMCP opposes House Bill 1048 because it implements a state mandate requiring the use of the abuse deterrent products that may not be necessary for every patient.